|
OMICS: A Journal of Integrative Biology
Phenotypical Enrichment Strategies for Microarray Data Analysis Applied in a Type II Diabetes Study
To cite this article:
Keith Boyce, Andres Kriete, Sheila Nagatomi, Bruce Kelder, Karen Coschigano, John J. Kopchick.
OMICS: A Journal of Integrative Biology.
Fall 2005,
9(3): 251-265.
doi:10.1089/omi.2005.9.251.
Published in Volume: 9 Issue 3: October 6, 2005
Keith Boyce Icoria, Inc., Pittsburgh, Pennsylvania. Immune Tolerance Network, UCSF, Pittsburgh, Pennsylvania. Dr. Andres Kriete Icoria, Inc., Pittsburgh, Pennsylvania. School of Biomedical Engineering, Drexel University, Philadelphia, Pennsylvania. Coriell Institute for Medical Research, Camden, New Jersey. Sheila Nagatomi Icoria, Inc., Pittsburgh, Pennsylvania. Bruce Kelder Edison Biotechnology Institute, Ohio University, Athens, Ohio. Karen Coschigano Edison Biotechnology Institute, Ohio University, Athens, Ohio. John J. Kopchick Edison Biotechnology Institute, and Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio. Combining results from gene microarrays, clinical chemistry, and quantitative tissue histomorphology in an integrated bioinformatics setting enables prioritization of gene families as well as individual genes in a type II diabetes animal study. This new methodology takes advantage of a time-controlled mouse study as the animals progress from a normal phenotype to that of type II diabetes. Profiles from different levels of the biological hierarchy of unpooled entities provide an encompassing, system-wide view of biological changes. Here, phenotypic changes on the tissue-structural and physiological level are used as statistical covariants to enrich the gene expression analysis, suggesting correlative processes between gene expression and phenotype unlocked by multi-sample comparisons. We apply correlative and gene set enrichment procedures and compare the results to differential analysis to identify molecular markers. Evaluation based on ontological classifications proves changes in prioritization of disease-related genes that would have been overlooked by conventional gene expression analyses strategies.  This paper was cited by:Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases Alexei Kharitonenkov, Armen B Shanafelt BioDrugs. Feb 2008, Vol. 22, No. 1: 37-44 CrossRef Cytomics in the realm of systems biology Andres Kriete Cytometry Part A. Dec 2005, Vol. 68A, No. 1: 19-20 CrossRef
|
|